Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 5Tumor-Agnostic 3Head & Neck 2Genitourinary 2Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Non Castrate Metastatic Prostate Cancer 1Castration-resistant Prostate Cancer 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × NVP-BKM120 × Genitourinary × Clear all
NCT01741753 2019-02-05

BKM120+Abiraterone Acetate for Metastatic CRPC

Dana-Farber Cancer Institute

Phase 1 Terminated
4 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01385293 2017-05-19

BKM120 in Metastatic Castration-resistant Prostate Cancer

Duke University

Phase 2 Terminated
30 enrolled 11 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡